FLT-3 mutant inhibitors (Oncodesign)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameFLT-3 mutant inhibitors (Oncodesign)
Drug Alias Namefms-like tyrosine kinase receptor 3 mutant inhibitors (Oncodesign)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitors
TargetsTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesOncodesign Services
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOncodesign Services
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A